Melanoma Drugs Market Size, Share, Growth Report 2032

Melanoma Drugs Market Insights

Zion Market Research has published a report on the global Melanoma Drugs Market, estimating its value at USD 5.53 Billion in 2023, with projections indicating that it will reach USD 13.49 Billion by 2032. The market is expected to expand at a compound annual growth rate (CAGR) of 10.42% over the forecast period 2024-2032. The report explores the factors fueling market growth, the hitches that could hamper this expansion, and the opportunities that may arise in the Melanoma Drugs Market industry. Additionally, it offers a detailed analysis of how these elements will affect market demand dynamics and market performance throughout the forecast period.

Request Free Sample

Melanoma is a tumor of melanin-forming cells called melanocytes. Melanoma is usually, but not always cancer of the skin and is the most dangerous form. Normal melanocytes are turned into cancerous cells when unrepaired DNA damage leads to mutation (change in structure or sequence of DNA) most often caused by ultraviolet radiation from the sunshine. As per Melanoma Research Foundation, approximately 90% of melanoma cases can be linked to exposure to ultraviolet (UV) rays from natural or artificial sources. This causes the skin cells to multiply rapidly and form malignant tumors. Tumors are developed in the basal layer of the epidermis where melanocytes generated. As per Skin Care Foundation report, one person dies of melanoma every hour (every 52 minutes). As per American Cancer Society, about 76,000 new melanomas were diagnosed in the United States for 2016 and about 10,000 people are expected to die of melanoma every year. Melanoma is more than 20 times more common in whites than in African Americans. American Cancer Society also reports that the rates of melanoma have been rising for the last 30 years. So the treatment of melanoma has become of prime importance owing to increase in a number of global melanoma patients. Different types of drugs are administered to melanoma patients depending upon therapy used to treat the patient.

Melanoma Drugs Market: Overview      

The global melanoma drugs market is majorly boosted by increasing cases of target disease everywhere on the planet. A number of the main boosting factors are combination treatment with better survival & lesser side effects and therefore the development of novel agents. On the opposite hand, the high cost of clinical trials and combination therapies paired with possible side effects or adverse effects are the first limitations that will hinder the event of the melanoma drugs market.

Nevertheless increasing aim on customized medicine paired alongside huge spending in anti-melanoma drugs research everywhere the planet are expected to reveal the new growth opportunities for the melanoma drugs market within the years to return. For instance, in December 2017, the FDA approved the anti-PD1 antibody, named nivolumab for the adjuvant therapy of individuals affected by melanoma. Nivolumab was earlier approved for the treatment of individuals affected by metastatic or unresectable melanoma. This approval has lent a hand to the event o the melanoma drugs market.

Request Free Sample

Melanoma Drugs Market: Growth Factors

The prevalence of skin allergies, melanoma, and other skin cancers in developing countries is high, which is a chance for drug companies to realize a bigger share in these regions. Increasing demand for cost-efficient therapeutics in developing regions, like Asia Pacific and Middle East & Africa, has encouraged major players to develop cheaper and effective drugs. These factors are expected to fuel the expansion of the general market within the coming years.

Growing incidence rate of target disease is expected to be the major driver for the global melanoma drugs market. In addition, development of novel agents and combination therapy with lesser side effects and better survival will surge the drug market worldwide in the coming years. However, the high price of combination therapies and the high cost of clinical trials coupled along with possible adverse events or side effects may pose the challenge to melanoma drugs market. Thus targeted therapy market is expected to surge owing to reduced risk of adverse effects and mortality. Nevertheless, FDA’s approval of new agents such as ipilimumab and increasing focus on targeted therapies to limit side effects coupled along with huge investment in anti-melanoma drugs research across the globe are expected to act an opportunity for melanoma drugs market in near future.

Request Free Sample

Melanoma Drugs Market: Report Scope

Segment Analysis Preview   

The melanoma drugs market is divided based on various therapeutic sections comprising immunotherapy, chemotherapy, and targeted therapy. FDA-accepted immunotherapy agents such as nivolumab and pembrolizumab are understudies of major players. Thus immunotherapy section is likely to develop at the quickest rate in the melanoma drugs market soon.

Regional Segment Analysis Preview   

Regionally, North America is likely to remain the dominant region in melanoma drugs n the years to come. The requirement for melanoma drugs was uppermost in North America particularly in the U.S. Hence, the Asia Pacific is likely to be the reasonable-developing area during the forecast period in the melanoma drugs market. In addition to this, Latin America and the Middle East & Africa are also likely to exhibit moderate development in the years to come for the melanoma drugs market.

Request Free Sample

Key Market Players & Competitive Landscape

The key companies operating in the Melanoma Drugs market include:

• Bristol-Myers Squibb
• Amgen
• Genentech Inc.
• Hoffmann-La Roche Ltd
• Novartis International AG.
• Janssen Biotech, Inc.,
• Sanofi
• Pfizer
• Teva Pharmaceuticals
• Takeda Pharmaceutical Company Limited among others.
• These players are claimed to bolster the global melanoma drugs market in the years to come.

Request Free Sample

The global Melanoma Drugs Market is segmented as follows:

By Therapy

• Chemotherapy
• Immunotherapy
• Targeted Therapy

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa